FDA
-
-
-
-
-
-
-
Barclays Downgrades Regenxbio Inc. (RGNX) to Equalweight
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
-
-
-
-
-
-
-
Stifel on Regenxbio Inc. (RGNX): 'Positive Functional Update at MDA Bolsters “Best-in-Class” Thesis Ahead of Ph.3 DMD Readout'
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $42 at Stifel
-
-
-
-
-
-
-
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
-
-
-
-
-
-
-
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
-
329,984 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

